Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer

  • Longer-term survival results underscoring role of KEYTRUDA® (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
  • Seven-year survival from SOLO-1 and final overall survival (OS) results from PAOLA-1 highlight role of LYNPARZA® (olaparib) in first-line maintenance of advanced ovarian cancer
  • First presentation of KEYTRUDA in combination with an antibody-drug conjugate (enfortumab vedotin) (Phase 1b/2 EV-103/KEYNOTE-869 Cohort K)

Reno, Nevada ( -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that research spanning 16 different cancer types will be presented at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris, France from Sept. 9-13. The breadth of data showcases the continued impact of Merck’s portfolio of oncology medicines and the potential of Merck's innovative oncology pipeline.

“We are proud to present longer-term survival data in patients with lung, ovarian, melanoma and head and neck cancers, as well as findings that reinforce the impact of our medicines in earlier stages of certain cancers and in new combinations,” said Dr. Eliav Barr, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “Notably, we look forward to sharing five-year survival results from the pivotal KEYNOTE-189 study that has established the foundational role of KEYTRUDA in the first-line treatment setting for patients with metastatic nonsquamous non-small cell lung cancer, and results from EV-103/KEYNOTE-869, a study of KEYTRUDA in combination with the antibody-drug conjugate, enfortumab vedotin, in patients with locally advanced or metastatic urothelial cancer.”
Presentations will feature new or updated findings from Merck’s growing pipeline and broad portfolio of cancer medicines: KEYTRUDA; WELIREG™ (belzutifan); LYNPARZA (in collaboration with AstraZeneca); LENVIMA® (lenvatinib, in collaboration with Eisai); and ODM‑208, an investigational steroid synthesis inhibitor (in collaboration with Orion).

Key Merck and collaborative data at ESMO 2022:

  • Five-year overall survival (OS) data from the pivotal Phase 3 KEYNOTE-189 and KEYNOTE-407 trials evaluating KEYTRUDA in combination with chemotherapy as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) (Presentations #973MO and #974MO, respectively);
  • Seven-year OS data from the Phase 3 SOLO-1 trial evaluating maintenance LYNPARZA in patients with advanced BRCA-mutated ovarian cancer, following first-line platinum-based chemotherapy (Presentation #517O) and final OS results from the Phase 3 PAOLA-1 trial evaluating maintenance LYNPARZA in combination with bevacizumab in patients with advanced ovarian cancer following first-line platinum-based chemotherapy and bevacizumab (Presentation #LBA29);
  • First-time data from Cohort K of the Phase 1b/2 EV-103/KEYNOTE-869 trial evaluating PADCEV® (enfortumab vedotin) in combination with KEYTRUDA as first-line treatment for patients with cisplatin-ineligible unresectable locally advanced or metastatic urothelial cancer (Presentation #LBA73), which reported positive topline results for the primary endpoint of objective response rate earlier this year;
  • First-time data from NCI-sponsored SWOG S1801, a Phase 2 study of neoadjuvant versus adjuvant KEYTRUDA for clinically detectable and resectable stage III to IV melanoma, to be featured in Presidential Symposium II (Presentation #LBA6).
Merck presentations at ESMO 2022:

Genitourinary cancers

Belzutifan, A Hypoxia-Inducible Factor-2α Inhibitor, For Von Hippel-Lindau (VHL) Disease-Associated Neoplasms: 36 Months Of Follow-Up Of The Phase 2 LITESPARK-004 Study. R. Srinivasan.

Presentation #LBA69, Mini Oral

Study EV-103 Cohort K: Antitumor Activity Of Enfortumab Vedotin (EV) Monotherapy Or In Combination With Pembrolizumab (P) In Previously Untreated Cisplatin-Ineligible Patients (Pts) With Locally Advanced Or Metastatic Urothelial Cancer (la/mUC). J. Rosenberg.

Presentation #LBA73, Proffered Paper

Proffered Paper: Biomarker Analysis And Updated Results From The Phase 3 PROpel Trial Of Abiraterone (Abi) And Olaparib (Ola) Vs Abi And Placebo (Pbo) As First-Line (1L) Therapy For Patients (Pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC). F. Saad.

Presentation #1357O, Proffered Paper

Pembrolizumab + Olaparib Vs Abiraterone (Abi) Or Enzalutamide (Enza) For Patients (Pts) With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC): Randomized Open-Label Phase 3 KEYLYNK-010 Study. E. Yu.

Presentation #1362MO, Mini Oral

Preliminary Phase 2 Results Of The CYPIDES Study Of ODM-208 In Metastatic Castration-Resistant Prostate (mCRPC) Cancer Patients. K. Fizazi.

Presentation #1364MO, Mini Oral

Two-Year Follow-Up Of KEYNOTE-365 Cohort D: Pembrolizumab (Pembro) Plus Abiraterone Acetate (Abi) And Prednisone In Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer (mCRPC). M. Linch.

Presentation #1389P, Poster

Phase 2 Study Of Belzutifan Plus Cabozantinib As First-Line Treatment Of Advanced Renal Cell Carcinoma (RCC): Cohort 1 Of LITESPARK-003. T. Choueiri.

Presentation #1447O, Proffered Paper

Phase 2 KEYNOTE-B61 Study Of Pembrolizumab (Pembro) + Lenvatinib (Lenva) As First-Line Treatment For Non-Clear Cell Renal Cell Carcinoma (nccRCC). L. Albiges.

Presentation #1448O, Proffered Paper

Updated Efficacy of Lenvatinib (LEN) + Pembrolizumab (PEMBRO) Vs Sunitinib (SUN) In Patients (Pts) With Advanced Renal Cell Carcinoma (aRCC) In The CLEAR Study. C. Guglielmo.

Presentation #1449MO, Mini Oral

Phase 2 Study of Belzutifan Plus Cabozantinib For Previously Treated Advanced Renal Cell Carcinoma (RCC): Update From Cohort 2 Of LITESPARK-003. D. McDermott.

Presentation #1453P, Poster

Source: "Merck To Present New Data At ESMO 2022 Congress From Its Broad Oncology Portfolio And Promising Pipeline, Demonstrating Commitment To Improving Long-Term Survival In Multiple Types Of Cancer - Merck.Com". 2022. Merck.Com.